Press Releases

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

Denali Therapeutics Announces First Patient Dosed In Phase 1b Study Of DNL151 For Parkinson’s Disease And Launch Of Its Engage Parkinson’s Website

Denali Therapeutics 09.04.2019

Denali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study

Denali Therapeutics 08.05.2019

Denali Therapeutics Announces First Patient Dosed In Phase 1b Study Of DNL747 For Alzheimer’s Disease

Denali Therapeutics 02.15.2019

SIRION Biotech and Denali Therapeutics Join Forces to Develop Gene Therapies for Diseases of the Central Nervous System

Denali Therapeutics 01.09.2019

Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for ALS

Denali Therapeutics 01.08.2019

Denali Therapeutics Announces First Patient Dosed In Phase 1b Study Of DNL201 For Parkinson’s Disease

Denali Therapeutics 12.10.2018

Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule And Intention To Initiate Patient Studies In Multiple Indications In Collaboration With Sanofi

Denali Therapeutics 11.19.2018

Flagship Pioneering Names Ryan Watts, CEO of Denali Therapeutics, as Recipient of the 2018 Pioneering Leader Award

Flagship Pioneering, Denali Therapeutics 11.15.2018

Denali Therapeutics Announces Broad Collaboration With Sanofi To Develop RIPK1 Inhibitors For The Treatment Of Neurological And Inflammatory Diseases

Denali Therapeutics 11.01.2018

CENTOGENE And Denali Therapeutics Announce Strategic Collaboration To Recruit LRRK2 Patients For Clinical Trials

Denali Therapeutics 10.03.2018

Loading